Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy
Movement Disorders2016Vol. 31(5), pp. 742–747
Citations Over TimeTop 12% of 2016 papers
María Stamelou, Jakob Schöpe, Stefan Wagenpfeil, Teodoro del Ser, Jee Bang, Iryna Y. Lobach, Phi Luong, Gesine Respondek, Wolfgang H. Oertel, A M Boxer, Günter U. Höglinger, for the AL‐108‐231 Investigators, Tauros Investigators, and MDS‐Endorsed PSP Study Group
Abstract
We propose the 1-year PSP-Rating Scale score change as the single primary readout in clinical neuroprotective or disease-modifying trials. The Schwab and England Activities of Daily Living could be used as a secondary outcome. © 2016 International Parkinson and Movement Disorder Society.
Related Papers
- → Clinical Conditions “Suggestive of Progressive Supranuclear Palsy”—Diagnostic Performance(2020)37 cited
- → Uncovering spatiotemporal patterns of atrophy in progressive supranuclear palsy using unsupervised machine learning(2023)27 cited
- → Usefulness of the superior cerebellar peduncle for differential diagnosis of progressive supranuclear palsy: A meta-analysis(2017)7 cited
- → Pisa syndrome in progressive supranuclear palsy: A case report(2017)
- → My dad and progressive supranuclear palsy (PSP)(2020)